Dermatophytes are filamentous keratinophilic fungi responsible for superficial fungal diseases involving the skin, hair, or nails. On the basis of the site of the lesions, conditions are called tinea corporis, tinea cruris, tinea capitis, tinea pedis, or tinea unguium. Since the mid-2010s, difficult-to-treat cases of tinea corporis and tinea cruris have emerged in India; molecular analysis revealed that this clinical presentation was caused by a unique clade related to the *Trichophyton mentagrophytes* complex (1). Since 2018, we have observed several cases of clinically resistant tinea corporis with extensive lesions that do not respond to terbinafine, the preferred first-line treatment. We investigated the microbiological origin of this resistance by looking for mutations in the squalene epoxidase gene, which is spreading on the Indian subcontinent.

We describe 7 cases of extensive tinea corporis since 2018 in a hospital in Paris, France, after failure to cure with terbinafine. Molecular analysis indicated *Trichophyton mentagrophytes* internal transcribed spacer type VIII (*T. indotinea*). This strain, which has mutations in the squalene epoxidase gene, is spreading on the Indian subcontinent.

**The Study**

During January 1, 2018–December 31, 2019, we saw 2,282 patients for dermatophytosis at Hôpital Saint-Louis Parasitologie-Mycologie (Paris, France). Of these, 350 (15.3%) patients were positive for *T. mentagrophytes* complex, identified by macroscopic and microscopic phenotypical features. Seven (2.0%) patients, all of whom were either recent immigrants or born in a country on the Indian subcontinent and had traveled back to their birthplace in recent years, had clinically terbinafine-resistant tinea corporis (Table 1). The cutaneous lesions were often multiple and extensive and involved the groin, axillary pits, trunk, limbs, and face but spared the extremities and nails (Figure 1). The patients’ main complaint was intractable pruritus.

We analyzed the 7 clinically resistant *T. mentagrophytes* complex isolates and 8 control isolates from patients with terbinafine-susceptible clinical presentations of tinea (6 cases of tinea pedis or tinea unguium and 1 each of tinea faciei and tinea corporis) collected September 1–October 15, 2018. We sequenced the internal transcribed spacer (ITS) using ITS1 and ITS4 primers, which allowed us to ascribe the isolates to 1 of the 7 different genotypes of *T. mentagrophytes* or the 2 genotypes of *T. interdigitale* (2,3). We aligned sequences using Geneious Prime version 2020.0.4 software (https://www.geneious.com) and compared them using the Mycobank DNA database (https://www.mycobank.org).

We amplified the SQLE gene of all studied isolates using previously reported primer pairs (4).

To ease the SQLE gene sequence analysis, we shortened the PCR products by designing 2 internal

---

**Author affiliations:** Hôpital Saint Louis Laboratoire de Parasitologie-Mycologie, Assistance Publique des Hôpitaux de Paris, Paris, France (S. Dellière, B. Joannard, M. Benderdouche, A. Mingui, M. Gits-Muselli, S. Hamane, A. Alanio, S. Bretagne); Université de Paris, Paris (S. Dellière, M. Gits-Muselli, A. Alanio, M. Bagot, S. Bretagne); Centre National de Référence Mycoses Invasives et Antifongiques Unité de Mycologie Moléculaire, Paris (A. Alanio, S. Bretagne); Hôpital Saint-Louis Service de Dermatologie, Assistance Publique des Hôpitaux de Paris, Paris (A. Petit, G. Gabison, M. Bagot); INSERM U976 (M. Bagot)

DOI: https://doi.org/10.3201/eid2801.210810

1These authors contributed equally to this article.
Difficult-to-Treat Tinea Corporis, France

Table 1. Clinical characteristics and treatment for patients with difficult-to-treat tinea corporis caused by *Trichophyton mentagrophytes* complex isolates, Paris, France*

| Patient no. | Age, y/sex | Geographic origin | Medical history | Clinical presentation | First-line treatment | Second-line treatment | Third-line treatment |
|-------------|-------------|-------------------|-----------------|----------------------|----------------------|----------------------|----------------------|
| 1           | 28/F        | Bangladesh        | None            | Erythematous, scaly plaques of trunk and arms; pruritus (Figure 1, panel A) | TBR 250 mg/d; outcome (9 wk): partial healing, positive culture of skin sample | GSF 500 mg x 2/d; outcome (4 wk): no healing | ITZ 200 mg/d; outcome (12 wk); improvement, negative culture of skin sample; relapse 5 mo after ending ITZ |
| 2           | 47/F        | India             | Diabetes mellitus, psoriasis | Erythematous scaly plaques of groins and axillary pits; pruritus | TBR 250 mg/d; outcome: no improvement, positive culture of skin sample | ITZ 200 mg/d; outcome (12 wk): healing and negative culture of skin sample; relapse 1 y later | NA |
| 3†          | 20/M        | India             | None            | Erythematous scaly plaques of groins, trunk, buttocks, and legs; pruritus (Figure 1, panel B) | TBR 250 mg/d; outcome (12 wk): no improvement, positive culture of skin sample | ITZ 200 mg/d; outcome (8 wk): healing and negative culture of skin sample | NA |
| 4           | 46/M        | Bangladesh        | Diabetes mellitus, dyslipidemia | Plaques with strong pruritic erythema and vesicles with surrounding papules of groins, buttoc, thigh, arms, and face† | TBR 250 mg/d; outcome (6 wk): no improvement, positive culture of skin sample | ITZ 200 mg/d + topical bifonazole; outcome (12 wk): complete healing | NA |
| 5           | 44/F        | Bangladesh        | Diabetes mellitus, dyslipidemia | Erythematous scaly plaques of groins and axillary pits with secondary extension to trunk and limbs† (Figure 1 panel D) | TBR 250 mg/d + topical ciclopirox; lost-to-follow up | NA | NA |
| 6           | 39/F        | India             | Chronic hepatitis B | Centrifuge annular erythema of trunk and arms;† pruritus (Figure 1 panel C) | FCZ 200 mg/wk + topical TBR; outcome (16 wk): improvement; relapse 1 y later | NA | NA |
| 7           | 57/M        | Sri Lanka         | Crohn’s disease, psoriasis | Erythematous scaly plaques of groins, buttocks, knees, shoulders, and neck | Topical bifonazole; outcome (8 wk): no improvement | TBR 250 mg/d + topical steroids (for severe associated psoriasis lesions); outcome (8 wk): partial improvement | TBR 250 mg/d; outcome (8 wk): improvement; relapse 1 year later |

*FCZ, fluconazole; GSF, griseofulvin; ITZ, itraconazole; NA, not applicable; TBR, terbinafine.
†Patient 2’s son.
‡Had applied topical steroids.

We generated a phylogenetic tree based on alignment of the ITS sequences (Figure 2). The 7 resistant isolates (Table 2) belonged to *T. mentagrophytes* ITS type VIII, whereas 6/8 control isolates belonged to a different subgroup close to genotypes I and II associated with the anthropophilic *T. interdigitale* and 2/8 to genotype VI (3). SQLE sequencing revealed substitutions in the 7 resistant isolates at sequences F397L, L393S, and A448T (Table 2). We also observed polymorphisms (at K276N) in 2 of the 8 control isolates (Table 2). We determined MICs of antifungal drugs for the 9 isolates with non–wild-type SQLE sequences. The 2 isolates with the A448T substitution had low terbinafine MICs, similar to the 2 control isolates with the K276N substitution (Table 2).
Only 1 isolate (from patient 7) with the A448T substitution had a high MIC for azoles.

Conclusions
We describe a series of cases of tinea corporis in France caused by *T. mentagrophytes* complex ITS type VIII (3), which showed sufficient molecular and phenotypic differences to be recently individualized into a separate species called *T. indotineae* (7). Although its frequency is currently low (2.0% of all *T. mentagrophytes* complex isolates in our hospital), it is alarming because of the therapeutic failure we observed when using available antifungal drugs (8). *T. indotineae* is endemic to India (1) and Iran (2,9), but several cases have been reported in Germany (3), Denmark (6), Poland (10), Belgium (11), and Switzerland (12). These cases are mainly among persons, similar to our patients, returning from the Indian subcontinent. Direct human-to-human transmission is probable between family members in our study, as reported elsewhere (9) and in a couple reported in Switzerland (12). However, the possibility that the patients were contaminated from a common source cannot be excluded. Until now, 2 German-born residents have been reported infected despite not having traveled, generating fear of possible extension beyond the initial endemic focus area (3).

Thus far, 10 missense mutations in the SQLE gene have been previously proven in vitro to lead to elevated MICs for terbinafine by genetic manipulation (4,13). The F397L and L393S mutations observed in 5 of our patients have been frequently reported in India and Iran (1,2), as well as in Europe among travelers or migrants (3,4,8,10). A448T substitution was observed in 2 patients, for which both isolates had low terbinafine MICs, and 1 of them had high MICs for azoles, as reported elsewhere (3). With the generalization of sequencing, probability of identifying polymorphisms, such as...
the K276N substitution, increases (Table 2). These observations could be misleading if observed in clinically resistant isolates without performing formal genetic experiments. Moreover, mechanisms other than SQLE mutations have been reported that possibly explain in vitro resistance (14). As a consequence, identifying T. indotineae seems more clinically relevant than identifying the polymorphism in the SQLE sequence to predicting the failure of antifungal drugs. Without being able to identify the original reservoir of this dermatophyte, one suggestion is that mutations in SQLE and high MICs could be consequences of multiple previous treatments. Delays in seeking specialized medical advice for chronic cutaneous lesions are common, so improper use of topical steroids or over-the-counter medications for alternative diagnoses could favor the accumulation of mutations in the microorganism.

Once T. indotineae is identified, the challenge of curing the cutaneous lesions remains. After terbinafine failure, in the absence of contraindications, patients in our study were mainly treated with itraconazole, as recommended (3). The long-term success rate of itraconazole was very modest, even when an initial improvement was noted. When checked

---

**Table 2.** MICs of the 9 isolates with non–wild-type SQLE sequences from patients with difficult-to-treat tinea corporis caused by *Trichophyton mentagrophytes* complex isolates, Paris, France, and control isolates*

| Drug      | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Control 5 | Control 8 |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Terbinafine | 4         | 4         | 4         | 4         | 1         | 0.014     | 0.03      | 0.03      | 0.03      |
| Itraconazole | 0.014     | 0.06      | 0.06      | 0.014     | 0.06      | 0.06      | 16        | 0.25      | 0.25      |
| Voriconazole | 0.25      | 0.125     | 0.25      | 0.25      | 0.25      | 0.25      | 2         | 0.25      | 0.25      |
| Posaconazole | 0.03      | 0.06      | 0.06      | 0.03      | 0.06      | 0.06      | 0.5       | 0.25      | 0.125     |
| Isavuconazole | 0.125     | 0.25      | 0.5       | 0.125     | 0.5       | 0.25      | 4         | 0.5       | 0.5       |

*SQLE, squalene epoxidase.*
months after the end of azole treatment, at least 4 of the 7 patients still harbored clinical lesions, and the failure to cure was mycologically confirmed. Of course, every cofactor favoring dermatomycosis should be controlled or avoided when possible, including diabetes (2/7 patients in our study) or use of topical steroids (4/7 patients).

Our findings provide additional evidence of the spread of some dermatophyte species through travel and immigration, as has been evidenced by previously nonendemic *T. tonsurans* replacing other species as the etiologic agent of tinea capitis in children in the Paris area (15). Surveillance should focus more specifically on identifying *T. indotineae* than SQLE sequences or MIC testing. Optimal treatment when terbinafine resistance is demonstrated, given the high failure rate of itraconazole, remains to be established.

Acknowledgments
We thank Cécile Gautier, Dea Garcia-Hermoso, and Sarah Seng for their technical help. We thank all the clinicians who cared for the patients, especially P. Oberlin, B. Levy-Klotz, C. Viney, and C. Dommergues.

About the Author
Dr. Dellière is a medical mycologist fellow at University Hospital Saint-Louis and a PhD candidate in the molecular mycology unit in the Pasteur Institute in Paris, France. Her primary research interests include diagnosis of, and resistance and host-pathogen interaction in mold infections. Dr. Joannard is a medical resident in clinical microbiology at public healthcare centers in Paris.

References
1. Singh A, Masih A, Monroy-Nieto J, Singh PK, Bowers J, Travis J, et al. A unique multidrug-resistant clonal *Trichophyton* population distinct from *Trichophyton mentagrophytes/Trichophyton interdigitale* complex causing an ongoing alarming dermatophytosis outbreak in India: genomic insights and resistance profile. Fungal Genet Biol. 2019;133:103266. https://doi.org/10.1016/j.fgb.2019.103266
2. Taghipour S, Pchelin IM, Zarei Mahmoudabadi A, Ansari S, Katiraeef F, Rafiei A, et al. *Trichophyton mentagrophytes* and *T. interdigitale* genotypes are associated with particular geographic areas and clinical manifestations. Mycoses. 2019;62:1084–91. https://doi.org/10.1111/myc.12993
3. Nenoff P, Verma SB, Ebert A, Süß A, Fischer E, Auerswald E, et al. Spread of terbinafine-resistant *Trichophyton mentagrophytes* type VIII (India) in Germany — “the tip of the iceberg?” J Fungi (Basel). 2020;6:207. https://doi.org/10.3390/jof6040207
4. Yamada T, Maeda M, Alshahini MM, Tanaka R, Yaguchi T, Bontems O, et al. Terbinafine resistance of *Trichophyton* clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61:e01115–7. https://doi.org/10.1128/AAC.01115-17
5. Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, et al. High terbinafine resistance in *Trichophyton interdigitale* isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477–84. https://doi.org/10.1111/myc.12772
6. Saunte DML, Hare RK, Jørgensen KM, Jørgensen R, Deleuran M, Zachariae CO, et al. Emerging terbinafine resistance in *Trichophyton*: clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection. Antimicrob Agents Chemother. 2019;63:e01126–19. https://doi.org/10.1128/AAC.01126-19
7. Tang C, Kong X, Ahmed SA, Thakur R, Chowdhary A, Nenoff P, et al. Taxonomy of the *Trichophyton mentagrophytes/T. interdigitale* species complex harboring the highly virulent, multiresistant genotype *T. indotineae*. Mycopathologia. 2021;186:315–26. https://doi.org/10.1007/s11046-021-00544-2
8. Saunte DML, Pereiro-Ferreirós M, Rodríguez-Cerdeira C, Sergeev AY, Arabatzis M, Prohić I, et al. Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic. J Eur Acad Dermatol Venereol. 2021;35:1582–6. https://doi.org/10.1111/jdv.17241
9. Fattahi A, Shirvani F, Ayatollahi A, Rezaei-Matehkoiae A, Badali H, Lotfali E, et al. Multidrug-resistant *Trichophyton mentagrophytes* genotype VIII in an Iranian family with generalized dermatophytosis: report of four cases and review of literature. Int J Dermatol. 2021;60:686–92. https://doi.org/10.1111/ijd.15226
10. Łagowski D, Gnat S, Nowakiewicz A, Osiriska M, Dylag M. Intrinsic resistance to terbinafine among human and animal isolates of *Trichophyton mentagrophytes* related to amino acid substitution in the squalene epoxidase. Infection. 2020;48:889–97. https://doi.org/10.1007/s10152-020-00149-1
11. Sacheli R, Harag S, Behavay F, Evrard S, Rousseaux D, Adjetey A, et al. Belgian national survey on tinea capitis: epidemiological considerations and highlight of terbinafine-resistant *T. mentagrophytes* with a mutation on SQLE gene. J Fungi (Basel). 2020;6:195. https://doi.org/10.3390/jof6040195
12. Hisieh A, Quenan S, Riat A, Toutous-Trellu L, Fontao L. A new mutation in the SQLE gene of *Trichophyton mentagrophytes* associated to terbinafine resistance in a couple with disseminated tinea corporis. J Mycol Med. 2019;29:352–5. https://doi.org/10.1016/j.jymymed.2019.100903
13. Shankarnarayana SA, Shaw D, Sharma A, Chakrabarti A, Dogra S, Kumaran MS, et al. Rapid detection of terbinafine resistance in *Trichophyton mentagrophytes* species by amplified refractory mutation system-polymerase chain reaction. Sci Rep. 2020;10:1297. https://doi.org/10.1038/s41598-020-58187-0
14. Hiruma J, Kitagawa H, Noguchi H, Kano R, Hiruma M, Kamata H, et al. Terbinafine-resistant strain of *Trichophyton interdigitale* strain isolated from a tinea pedis patient. J Dermatol. 2019;46:351–3. https://doi.org/10.1111/1346-8138.14809
15. Gits-Muselli M, Benderdouche M, Hamane S, Mingui A, Venereol. 2021;35:1582–6. https://doi.org/10.1111/jdv.17241

Address for correspondence: Sarah Dellière, Hôpital Saint-Louis Parasitologie-Mycologie, 1 avenue Claude Vellefaux, Paris 75010, France; email: sarah.delliere@aphp.fr